Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

NCT06927999 is registered in ClinicalTrials.gov with ARS Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06927999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06927999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
Lead sponsor
ARS Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 9, 2025
Completion date
June 30, 2027
Enrollment
42 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria chronic